Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Masuda

Showing results (251-260 of 298) with videos related to

Pageof 30
Sort By:
Urologic Oncology|November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk modelNobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Clinical Genitourinary Cancer|April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell CarcinomaSuguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
Internal Medicine (Tokyo, Japan)|September 21, 2021
Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4Hiroki Tanahashi, Kakuhiro Yamaguchi, Tomoko Koura, et al.
Urologic Oncology|April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settingsNobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Thoracic Cancer|April 30, 2022
Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1Takeshi Masuda, Kazunori Fujitaka, Tomoko Suzuki, et al.
Journal of Asthma and Allergy|November 1, 2022
Association Between Patient Preference for Inhaler Medications and Asthma OutcomesYu Nakanishi, Hiroshi Iwamoto, Shintaro Miyamoto, et al.
Current Issues in Molecular Biology|October 26, 2021
Renadirsen, a Novel 2'OMeRNA/ENA<sup>®</sup> Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In VivoKentaro Ito, Hideo Takakusa, Masayo Kakuta, et al.
Scientific Reports|May 13, 2021
Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patientsKakuhiro Yamaguchi, Satoshi Nakao, Hiroshi Iwamoto, et al.
Molecular Cancer Research : MCR|October 27, 2020
SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer CellsHideki Terai, Junko Hamamoto, Katsura Emoto, et al.
The FEBS Journal|January 19, 2025
PI5P4K inhibitors: promising opportunities and challengesKoh Takeuchi, Lisa Nagase, Shun Kageyama, et al.
Pageof 30

Showing results (251-260 of 298) with videos related to

Sort By:
Pageof 30
Urologic Oncology|November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk modelNobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Clinical Genitourinary Cancer|April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell CarcinomaSuguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
Internal Medicine (Tokyo, Japan)|September 21, 2021
Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4Hiroki Tanahashi, Kakuhiro Yamaguchi, Tomoko Koura, et al.
Urologic Oncology|April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settingsNobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Thoracic Cancer|April 30, 2022
Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1Takeshi Masuda, Kazunori Fujitaka, Tomoko Suzuki, et al.
Journal of Asthma and Allergy|November 1, 2022
Association Between Patient Preference for Inhaler Medications and Asthma OutcomesYu Nakanishi, Hiroshi Iwamoto, Shintaro Miyamoto, et al.
Current Issues in Molecular Biology|October 26, 2021
Renadirsen, a Novel 2'OMeRNA/ENA<sup>®</sup> Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In VivoKentaro Ito, Hideo Takakusa, Masayo Kakuta, et al.
Scientific Reports|May 13, 2021
Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patientsKakuhiro Yamaguchi, Satoshi Nakao, Hiroshi Iwamoto, et al.
Molecular Cancer Research : MCR|October 27, 2020
SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer CellsHideki Terai, Junko Hamamoto, Katsura Emoto, et al.
The FEBS Journal|January 19, 2025
PI5P4K inhibitors: promising opportunities and challengesKoh Takeuchi, Lisa Nagase, Shun Kageyama, et al.
Pageof 30